Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses

Abstract excerpt

BACKGROUND: Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival of less than 2 years. However, the molecular underpinnings of the heterogeneous response to the current standard-of-care treatment regimen consisting of maximal safe resection, adjuvant radiation, and chemotherapy with temozolomide remain unknown. METHODS: Comprehensive...

Topics

Join the communities discussing this publication.

• Brain Metastases and Treatment
• Cutaneous Melanoma Detection and Management
• Glioma Diagnosis and Treatment